The brand name for adenosine is Adenocard [1]. Adenocard is an intravenous medication [1].
What is Adenocard used for?
Adenocard is primarily used to treat certain types of supraventricular tachycardia (SVT) [1]. SVT is a condition characterized by a fast heart rate that originates in the atria of the heart [2]. Adenocard works by slowing conduction through the atrioventricular (AV) node, which can interrupt the reentrant pathways responsible for SVT [3].
How is Adenocard administered?
Adenocard is administered intravenously, typically as a rapid bolus injection [1]. Due to its very short half-life, it must be given quickly directly into a vein or through an existing IV line with a rapid saline flush [1][3].
What are the potential side effects of Adenosine?
Patients may experience various side effects when taking Adenocard, including flushing, shortness of breath or difficulty breathing, chest pain, dizziness, nausea, and a feeling of impending doom [1]. Transient arrhythmias, such as bradycardia or AV block, can also occur [3].
Are there any alternatives to Adenocard for SVT?
Other medications used to manage SVT include beta-blockers and calcium channel blockers [4]. In some cases, vagal maneuvers or electrical cardioversion may also be employed [4].
When does the patent for Adenocard expire?
Information regarding specific patent expiry dates for Adenocard is available through specialized databases like DrugPatentWatch.com [5]. DrugPatentWatch.com tracks patent information for pharmaceuticals, including expiry dates and potential for generic competition [5].